{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:50:11Z","timestamp":1778143811127,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Laboratory Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.plabm.2024.e00425","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T18:43:46Z","timestamp":1725648226000},"page":"e00425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evaluation of the EUROIMMUN automated chemiluminescence immunoassays for measurement of four core biomarkers for Alzheimer\u2019s disease in cerebrospinal fluid"],"prefix":"10.1016","volume":"41","author":[{"given":"Katharina","family":"R\u00f6mpler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Arendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Borchardt-Loh\u00f6lter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-4451","authenticated-orcid":false,"given":"Anette","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Busse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Busse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.plabm.2024.e00425_bib1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer's disease: current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J. Intern. Med."},{"issue":"9","key":"10.1016\/j.plabm.2024.e00425_bib2","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.plabm.2024.e00425_bib3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s43440-020-00107-0","article-title":"Clinical significance of fluid biomarkers in Alzheimer's Disease","volume":"72","author":"Lewczuk","year":"2020","journal-title":"Pharmacol. Rep."},{"issue":"6","key":"10.1016\/j.plabm.2024.e00425_bib4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.plabm.2024.e00425_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.plabm.2024.e00425_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.plabm.2024.e00425_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.plabm.2024.e00425_bib8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid abeta42\/40 corresponds better than Abeta42 to amyloid PET in alzheimer's disease","volume":"55","author":"Lewczuk","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.plabm.2024.e00425_bib9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3233\/JAD-160286","article-title":"Optimized standard operating procedures for the analysis of cerebrospinal fluid Abeta42 and the ratios of abeta isoforms using low protein binding tubes","volume":"53","author":"Vanderstichele","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.plabm.2024.e00425_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2019.04.022","article-title":"The complexity of tau in Alzheimer's disease","volume":"705","author":"Naseri","year":"2019","journal-title":"Neurosci. Lett."},{"issue":"16","key":"10.1016\/j.plabm.2024.e00425_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz2387","article-title":"Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.plabm.2024.e00425_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","volume":"8","author":"Engelborghs","year":"2017","journal-title":"Alzheimers Dement. (Amst)"},{"issue":"11","key":"10.1016\/j.plabm.2024.e00425_bib13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease","volume":"14","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"9","key":"10.1016\/j.plabm.2024.e00425_bib14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.plabm.2024.e00425_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","article-title":"Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative","volume":"8","author":"Vanderstichele","year":"2012","journal-title":"Alzheimers Dement."},{"issue":"12","key":"10.1016\/j.plabm.2024.e00425_bib16","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1515\/cclm-2018-0147","article-title":"Commutability of the certified reference materials for the standardization of \u03b2-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and \u03b2-amyloid 1-40 measurements","volume":"56","author":"Andreasson","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"issue":"11","key":"10.1016\/j.plabm.2024.e00425_bib17","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/alz.12145","article-title":"First amyloid \u03b21-42 certified reference material for re-calibrating commercial immunoassays","volume":"16","author":"Boulo","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"5","key":"10.1016\/j.plabm.2024.e00425_bib18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/2211068214559979","article-title":"Biomarkers in the diagnosis and prognosis of alzheimer's disease","volume":"20","author":"Schaffer","year":"2015","journal-title":"J. Lab. Autom."},{"issue":"6","key":"10.1016\/j.plabm.2024.e00425_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100784","article-title":"Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice","volume":"9","author":"Vos","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.plabm.2024.e00425_bib20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/alz.12545","article-title":"Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: an international overview","volume":"18","author":"Delaby","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.plabm.2024.e00425_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-2012-120082","article-title":"Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease","volume":"31","author":"Wang","year":"2012","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.plabm.2024.e00425_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/00365513.2020.1740939","article-title":"Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis","volume":"80","author":"Agnello","year":"2020","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"1","key":"10.1016\/j.plabm.2024.e00425_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","article-title":"Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease","volume":"11","author":"Leitao","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.plabm.2024.e00425_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinbiochem.2019.05.005","article-title":"Elecsys((R)) Total-Tau and Phospho-Tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid","volume":"72","author":"Lifke","year":"2019","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.plabm.2024.e00425_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/cclm-2021-0651","article-title":"Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid","volume":"60","author":"Gobom","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.plabm.2024.e00425_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"11","key":"10.1016\/j.plabm.2024.e00425_bib27","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00702-006-0537-z","article-title":"CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies","volume":"113","author":"Bibl","year":"2006","journal-title":"J. Neural. Transm."},{"issue":"5","key":"10.1016\/j.plabm.2024.e00425_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00702-010-0543-z","article-title":"Different CSF beta-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease","volume":"118","author":"Mollenhauer","year":"2011","journal-title":"J. Neural. Transm."},{"issue":"9","key":"10.1016\/j.plabm.2024.e00425_bib29","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00415-019-09418-6","article-title":"Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Abeta(42) and T-Tau assays for Alzheimer's disease diagnosis","volume":"266","author":"Bayart","year":"2019","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.plabm.2024.e00425_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jagp.2020.07.011","article-title":"The role of neuropsychiatric symptoms in research diagnostic criteria for neurodegenerative diseases","volume":"29","author":"Cummings","year":"2021","journal-title":"Am. J. Geriatr. Psychiatr."},{"issue":"7","key":"10.1016\/j.plabm.2024.e00425_bib31","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00259-021-05258-7","article-title":"2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.plabm.2024.e00425_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13195-021-00817-4","article-title":"Prognostic value of amyloid\/tau\/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease","volume":"13","author":"Delmotte","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"issue":"4","key":"10.1016\/j.plabm.2024.e00425_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/alz.12406","article-title":"Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays","volume":"18","author":"van Harten","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.plabm.2024.e00425_bib34","article-title":"P-tau\/Abeta42 and Abeta42\/40 ratios in CSF are equally predictive of amyloid PET status","volume":"13","author":"Campbell","year":"2021","journal-title":"Alzheimers Dement. (Amst)"},{"key":"10.1016\/j.plabm.2024.e00425_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.604119","article-title":"Assessment of the concordance and diagnostic accuracy between elecsys and Lumipulse fully automated platforms and innotest","volume":"13","author":"Dakterzada","year":"2021","journal-title":"Front. Aging Neurosci."},{"issue":"14","key":"10.1016\/j.plabm.2024.e00425_bib36","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.plabm.2024.e00425_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jalz.2015.10.009","article-title":"Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia","volume":"12","author":"Llorens","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.plabm.2024.e00425_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-017-0265-7","article-title":"Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, alpha-synuclein, and total tau in combination with Abeta(1-42)\/Abeta(1-40)","volume":"9","author":"Vanderstichele","year":"2017","journal-title":"Alzheimer's Res. Ther."}],"container-title":["Practical Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352551724000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352551724000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T07:31:25Z","timestamp":1726817485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352551724000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":38,"alternative-id":["S2352551724000714"],"URL":"https:\/\/doi.org\/10.1016\/j.plabm.2024.e00425","relation":{},"ISSN":["2352-5517"],"issn-type":[{"value":"2352-5517","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the EUROIMMUN automated chemiluminescence immunoassays for measurement of four core biomarkers for Alzheimer\u2019s disease in cerebrospinal fluid","name":"articletitle","label":"Article Title"},{"value":"Practical Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plabm.2024.e00425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"e00425"}}